ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1 by Williams, Simon-Peter et al.
  
 University of Groningen
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and
STEAP1
Williams, Simon-Peter; Ogasawara, Annie; Tinianow, Jeff N.; Flores, Judith E.; Kan, David;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Williams, S-P., Ogasawara, A., Tinianow, J. N., Flores, J. E., Kan, D., Lau, J., ... Terwisscha Van
Scheltinga, A. (2016). ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting
TENB2 and STEAP1. Oncotarget, 7(18), 25103-25112. https://doi.org/10.18632/oncotarget.8390
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Oncotarget25103www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 18
ImmunoPET helps predicting the efficacy of antibody-drug 
conjugates targeting TENB2 and STEAP1
Simon-Peter Williams1, Annie Ogasawara1, Jeff N. Tinianow1, Judith E. Flores1, 
David Kan1, Jeffrey Lau1, MaryAnn Go1, Alexander N. Vanderbilt1, Herman S. Gill1, 
Li Miao1, Joshua Goldsmith1, Bonnee Rubinfeld1, Weiguang Mao1, Ron Firestein1, 
Shang-Fan Yu1, Jan Marik1, Anton G.T. Terwisscha van Scheltinga1,2
1Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA, 94080, USA
2 Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, 
Groningen, 9700RB, The Netherlands
Correspondence to: Simon-Peter Williams, e-mail: williams.simon@gene.com
Keywords: antibody-drug conjugates, immunoPET, TENB2, STEAP1, zirconium-89
Received: December 10, 2015    Accepted: March 04, 2016    Published: March 26, 2016
ABSTRACT
The efficacy of antibody-drug conjugates (ADCs) targeted to solid tumors 
depends on biological processes that are hard to monitor in vivo. 89Zr-immunoPET of 
the ADC antibodies could help understand the performance of ADCs in the clinic by 
confirming the necessary penetration, binding, and internalization. This work studied 
monomethyl auristatin E (MMAE) ADCs against two targets in metastatic castration-
resistant prostate cancer, TENB2 and STEAP1, in four patient-derived tumor models 
(LuCaP35V, LuCaP70, LuCaP77, LuCaP96.1). Three aspects of ADC biology were 
measured and compared: efficacy was measured in tumor growth inhibition studies; 
target expression was measured by immunohistochemistry and flow cytometry; 
and tumor antibody uptake was measured with 111In-mAbs and gamma counting or 
with 89Zr-immunoPET. Within each model, the mAb with the highest tumor uptake 
showed the greatest potency as an ADC. Sensitivity between models varied, with 
the LuCaP77 model showing weak efficacy despite high target expression and high 
antibody uptake. Ex vivo analysis confirmed the in vivo results, showing a correlation 
between expression, uptake and ADC efficacy. We conclude that 89Zr-immunoPET 
data can demonstrate which ADC candidates achieve the penetration, binding, and 
internalization necessary for efficacy in tumors sensitive to the toxic payload.
INTRODUCTION
Antibody-drug conjugates (ADCs) are a promising 
new class of anti-cancer therapeutics that aim to 
selectively deliver potent toxins to tumor cells by using 
monoclonal antibodies (mAbs) as targeting moieties. This 
should provide an improved therapeutic window in patient 
tissues expressing the cognate antigen. Multiple ADCs are 
in development for a variety of solid and hematological 
cancer indications [1]. The approach has already shown 
significant promise: recently-approved ADC molecules 
include brentuximab vedotin (anti-CD30-MMAE) for 
Hodgkins lymphoma and trastuzumab-emtansine (T-DM1) 
for metastatic breast cancer [2-4].
ADC target antigens are typically chosen because 
they exhibit tumor-specific expression and, if internalized, 
represent a selective entry portal into cancer cells [1]. 
However they are not necessarily molecular drivers 
of cancer, and consequently there may be no selection 
pressure resisting the loss of target expression in a new 
metastatic or post-treatment environment. Such a loss 
of expression could impair the ADC efficacy and this 
potential adds to the importance of comprehensively 
assessing and re-assessing the tumor target status.
Positron emission tomography (PET) imaging 
is widely used for characterizing tumors, offering 
excellent sensitivity and relatively good resolution [5-10]. 
ImmunoPET is used for tracking and quantification of 
mAbs with PET in vivo. The availability of zirconium-89 
(89Zr), and the adoption of standardized labeling protocols 
are enabling clinical mAb imaging with immunoPET 
to become more widespread, offering the potential for 
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whole-body non-invasive quantification of mAb uptake 
in normal and tumor tissues [5-10]. Because of the 
mechanistic importance of mAb delivery and tumor uptake 
to ADC therapies, immunoPET may be of particular value 
because the PET isotope is delivered to the cell by the same 
mAb and internalization mechanisms as the toxin. Thus an 
imaging signal in the tumor reveals processes necessary (but 
not sufficient) for drug delivery – a combination of tissue 
exposure, antigen binding, and antibody internalization [11].
For prostate cancer, TENB2 and STEAP1 have 
been recently identified as targets of interest for ADC 
development [12-14]. TENB2, a trans-membrane protein 
containing an epidermal growth factor-like motif and two 
follistatin-like domains, is found to be over-expressed in 
clinical prostate carcinoma with particular prominence 
in high-grade tumors [12]. STEAP1, six-transmembrane 
epithelial antigen of the prostate-1, is an antigen that is 
over expressed in the majority of human epithelial prostate 
cancers [13]. Treatment for advanced prostate cancer is 
particularly challenging due to the large number and 
potential heterogeneity of metastatic growths in soft tissue 
and especially in bone [15].
Molecular imaging of antibody delivery might 
predict treatment effects and therefore support drug 
development of the ADCs targeting TENB2 and STEAP1. 
To test this we examined the tumor growth inhibition 
properties of ADCs targeting these antigens in a panel 
of patient-derived prostate cancer models. Results were 
compared with parallel immunoPET studies performed 
to quantify tumor uptake of the corresponding mAbs 
targeting TENB2 and STEAP1 in the same tumor models. 
Both efficacy and imaging studies used anti-gD as an 
isotype-matched non-specific control antibody.
RESULTS
Radiolabeling of TENB2, STEAP1 and gD 
targeting mAbs
111In and 89Zr radiolabeled mAbs targeting TENB2, 
STEAP1 and gD all showed greater than 90% radiochemical 
purity. Binding was essentially unaltered in the potency 
assays for anti-TENB2 (IC50 of 1.03 ± 0.17 versus 0.96 
± 0.09 nM before and after radiolabeling respectively) and 
anti-STEAP1 (2.50 ± 0.09 versus 1.95 ± 0.15 nM).
Dose dependence of tumor uptake with 
111In-labeled anti-STEAP1
Dose-dependent tumor uptake was measured for 
111In-anti-STEAP1. Figure 1A shows the absolute tumor 
uptake (μg mAb per g tumor tissue) which was highest for 
the highest dose level tested, 40 mg/kg. Figure 1B shows 
the relative tumor uptake (expressed as %ID/g) which was 
highest at the 0.08 mg/kg, 0.2 mg/kg and 1 mg/kg dose 
levels.
Tracer tumor uptake and ADC tumor growth 
inhibition studies
Tumor tracer uptake of 111In labeled TENB2, 
STEAP1 and gD mAbs showed varying results (Figure 2). 
For all tumors, specific tumor uptake was observed relative 
to the non-specific gD control (P < 0.05). For TENB2, 
highest tumor uptake of 96.1 ± 2.8 %ID/g was measured 
in LuCaP77 tumors, the lowest (12.2 ± 1.6 %ID/g) in 
LuCaP35V. The anti-TENB2 tracer uptake in LuCaP70 
Figure 1: A. Dose dependent uptake studies of 111In-labeled anti-STEAP1. Absolute tumor uptake of 111In-anti-STEAP1 in LuCaP35V 
patient-derived xenografts expressed in μg/g. Mice received final dosages of 0.08 mg/kg, 0.2 mg/kg, 1 mg/kg, 10 mg/kg, or 40 mg/kg of 
anti-STEAP1. B. Fractional tumor uptake of anti-STEAP1 expressed as % of the injected dose per gram (%ID/g).
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was 12.3 ± 0.3 %ID/g and in LuCaP96.1 tumors 13.8 ± 0.3 
%ID/g. For STEAP1 ADC tumor uptake, highest values 
(38.7 ± 1.5 %ID/g) were measured in LuCaP35V tumors, 
lowest tumor uptake in LuCaP96.1 tumors (4.7 ± 0.3 
%ID/g). LuCaP70 and LuCaP77 tumors showed an uptake 
of 8.2 ± 0.3 %ID/g and 18.8 ± 0.6 %ID/g respectively.
Efficacy studies used tumor volumes measured over 
4-7 weeks following TENB2 or STEAP1 ADC MMAE-
conjugated drug treatment. LuCaP70 and LuCaP96.1 
tumors were sensitive for TENB2 ADC treatment, whereas 
in LuCaP77 efficacy of this ADC was relatively poor as 
tumors started to regrow. STEAP1 ADC was efficacious 
Figure 2: Tumor-tissue uptake of 111In-labeled STEAP1, TENB2, and control (gD) mAbs at 72 hours post-injection 
(5 mg/kg) (left column graphs) and tumor growth curves following dosing with the corresponding antibody-drug 
conjugates (5 mg/kg dosed once, on Day 1) (right column graphs) for four LuCaP tumor types: A. LuCaP35V, B. LuCaP70, 
C. LuCaP77, and D. LuCaP 96.1 top to bottom. Data are shown as means with their corresponding standard errors of the mean. Numbers 
of animals per group were 4-5 for the 111In-mAb study and 8-10 for the tumor growth study.
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in LuCaP35V and LuCaP70 tumors. In each LuCaP tumor 
line, the highest tumor uptake of mAb corresponded with 
the greatest on-treatment reduction in tumor volume.
PET imaging
Figure 3 shows representative images (maximum 
intensity projections), obtained five days after tracer injection 
and selected for tumor uptake closest to the median values in 
each group. Tumor uptake was higher in mice administered 
89Zr–anti-TENB2 or 89Zr–anti-STEAP1 compared to mice 
given the control mAb 89Zr–anti-gD (p < 0.05); the exception 
was 89Zr-anti-STEAP1 uptake in LuCaP96.1 tumors which 
was no higher than control. 89Zr tumor uptake as determined 
by PET quantification correlated with the 111In labeled mAb 
biodistribution studies (R2 = 0.85).
Figure 3: Maximum intensity projections from mouse coronal views of 89Zr-immunoPET images obtained 5 days post 
injection of TENB2, STEAP1 and control (gD) mAbs in four LuCaP tumor types: A. LuCaP35V, B. LuCaP70, C. LuCaP77, 
and D. LuCaP96.1. Tumors are growing on the flank visible as areas of intense dark uptake in some images. The intensity scale bar is 
calibrated as percentage of the injected dose per gram (%ID/g).
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Ex vivo tumor analysis
Antigen expression results are shown in Figure 4. 
Representative data samples from each group are shown. 
Expression of TENB2 was highest in LuCaP77 tumors 
(3+), moderate in LuCaP70 (1-2+) and LuCaP96.1 (1+), 
and lowest in LuCaP35V tumors (0 to 1+) (Figure 4A). 
Immunohistochemistry scoring of STEAP1 was highest 
in LuCaP70 tumors (3+), moderate in LuCaP35V (2+) 
and LuCaP77 (2-3+) tumors, and lowest in LuCaP96.1 
tumors (1+). Figure 4B shows different expression levels 
of TENB2 and STEAP1 in each cell line as determined by 
FACS analysis of tumor cells. Blue and green colored lines 
each represent an individual sample while red colored 
curves represents the secondary mAb standard as control. 
Comparable results were found for TENB2 and STEAP1 
expression as determined by immunohistochemistry and 
FACS analysis.
An overview of the combined results of tumor 
growth inhibition, 111In-mAb tumor uptake, 89Zr-mAb 
tumor uptake and target expression as determined by 
immunohistochemistry and FACS is presented in Table 1 
for TENB2 and in Table 2 for STEAP1.
DISCUSSION
To the best of our knowledge, this is the first study 
to demonstrate a correlation between tumor uptake of a 
89Zr antibody and ADC tumor growth inhibition. In four 
different patient-derived prostate cancer models, with 
varying TENB2 and STEAP1 expression, immunoPET 
predicts MMAE-conjugated ADC treatment efficacy.
Figure 4: Ex vivo analysis of TENB2 and STEAP1 tumor expression. A. TENB2 (top row) and STEAP1 (bottom row) expression as 
determined by immunohistocemical staining on LuCaP35V, LuCaP70, LuCaP77, and LuCaP96.1 patient-dervied xenografts. B. Fluorescence-
activated cell sorting (FACS) analysis of TENB2 (top row) and TENB2 expression (bottom row) in LuCaP35V, LuCaP70, LuCaP77, and 
LuCaP96.1 tumors. Cells were isolated following the disaggregation of solid tumors grown in mice. Two tumors were studied for each type. 
The data for these replicates are shown in blue and green while the FACS reference standard included with each sample is shown in red.
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ADC treatment is a promising new approach for 
anti-cancer treatment. However, without imaging to 
confirm good mAb uptake, disappointing response rates 
might be attributed to any combination of poor tissue 
penetration, absence of target, failure to bind target, lack 
of internalization, or drug resistance [1]. A lack of mAb 
uptake not explained by pharmacokinetic exposure may 
indicate a poor choice of target antigen or indicate a need 
to revise the mAb molecule. In contrast, a lack of drug 
efficacy observed in spite of visualizing strong tumor 
uptake may indicate the presence of active drug resistance 
mechanisms and suggest the need to try a different toxin.
In LuCaP35V tumors the anti-TENB2-MMAE 
ADC was ineffective which correlated with the low tracer 
uptake and target expression. In LuCaP70, LuCaP77 
and LuCaP96.1 tumors anti-TENB2-MMAE ADC was 
efficacious, showing tumor growth inhibition. These 
tumors had at least moderate expression of TENB2 
based on ex vivo immunohistochemistry and FACS 
tumor analysis. However, in the LuCaP77 tumor model, 
despite particularly high levels of 111In-TENB2 uptake, 
ADC efficacy was relatively poor as tumors started 
to regrow. Based on the observed tumor uptake level 
of 96 %ID/g (Figure 2) approximately 800 nmol of 
TENB2 mAb was delivered per kg of tumor tissue. This 
should have delivered MMAE considerably in excess 
of the IC50 concentration range for free toxin of 0.2 to 
2 nM determined in vitro [3]. Even allowing for partial 
deconjugation of the ADC in circulation and rapid loss 
of MMAE catabolites from the tumor tissue, this still 
suggests that the amount of MMAE delivered to the 
tumor tissue should have been sufficient to inhibit tumor 
growth. Poor MMAE efficacy in the LuCaP77 model may 
implicate some MMAE-selective resistance mechanism 
mediated by certain efflux pumps or multidrug resistance 
of these tumors [16, 17].
STEAP1 expression also correlated with ADC 
treatment effect, as LuCaP35V and LuCaP70 tumors were 
sensitive to anti-STEAP1-MMAE ADC treatment. In the 
LuCaP70 model 111In-anti-STEAP1 uptake was the lowest 
(8.2 %ID/g) accompanied by tumor growth inhibition. 
This level of MMAE delivery was an order of magnitude 
less than that discussed above for anti-TENB2 in LuCap77 
tumors, but was clearly sufficient to result in potency in 
sufficiently sensitive tumors.
While LuCaP77 tumors show high expression 
of TENB2 and STEAP1 these tumors did not respond 
to therapy. No metric of target expression predicted the 
degree of drug resistance that was encountered in these 
tumors. With the immunoPET data, there is powerful 
evidence of active tumor delivery of mAb in vivo, which 
provides a rationale for considering the use of the same 
mAb armed with alternative toxins, or entirely different 
cell-death effector moieties such as radioisotopes [18]. 
Although the presence of a receptor does not preclude 
resistance in clinical practice, establishing the presence 
or absence of an antigen is of tremendous importance. 
When there is no cellular uptake of 89Zr-mAb, no efficacy 
of mAb-MMAE can be expected. Clearly, the negative 
predictive value is greater than the positive predictive 
value, which is especially the case for ADCs. Therefore, 
establishing tumor uptake and TENB2 or STEAP1 
presence may well have value in choosing appropriate 
treatments in the future.
















LuCaP35V 12.2 ± 1.6 3.9 ± 0.1 18.0 ± 1.1 5.8 ± 0.6 20 0-1+
LuCaP70 12.3 ± 0.3 3.7 ± 0.2 8.5 ± 0.9 3.8 ± 0.1 100 1-2+
LuCaP77 96.1 ± 2.8 4.1 ± 0.3 34.2 ± 1.6 8.6 ± 0.5 55 3+
LuCaP96.1 13.8 ± 0.3 3.1 ± 0.2 13.2 ± 0.2 6.2 ± 0.1 75 1+
















LuCaP35V 38.7 ± 1.5 3.9 ± 0.1 25.0 ± 0.6 5.8 ± 0.6 100 2+
LuCaP70 8.2 ± 0.3 3.7 ± 0.2 7.6 ± 0.3 3.8 ± 0.1 100 3+
LuCaP77 18.8 ± 0.6 4.1 ± 0.3 11.9 ± 0.3 8.6 ± 0.5 0 2-3+
LuCaP96.1 4.7 ± 0.3 3.1 ± 0.2 6.5 ± 0.2 6.2 ± 0.1 0 1+
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In conclusion, quantitative data from immunoPET 
measuring relative mAb uptake patterns of TENB2- 
and STEAP1-targeting mAbs predict to a degree tumor 
growth inhibition by an ADC. ImmunoPET’s capacity 
to demonstrate the essential aspects of ADC delivery, 
binding and internalization in vivo offers advantages 
complementary to existing tools. ImmunoPET may 
thus help confirm the necessary prerequisites for 
efficacy with particular mAb-target combinations. 
It may also identify changes in target expression or 
function (internalization) from genetic or treatment-
induced effects. These studies were sufficiently 
encouraging to enter a research collaboration with 
Memorial Sloan Kettering Cancer Center to advance 
this preclinical research into phase I clinical studies 
of 89Zr-anti-STEAP1 uptake in metastatic castration 




All applicable international, national and/or 
institutional guidelines for the care and use of animals 
were followed.
Antibody-drug conjugates
For tumor growth inhibition studies, mAbs against 
TENB2 (Pr1, affinity 2.3 nM) and STEAP1 (MSTP2109A; 
affinity 2.4 nM) were conjugated with the auristatin 
moiety MC-vc-PAB-MMAE as previously described [3]. 
These mAbs were engineered to have exactly two site-
specific thiol residues available for conjugation [20]. The 
average drug-to-mAb ratio was 1.8-2.0 MMAE per mAb. 
The HSV-1 viral coat protein gD was used as non-binding 
isotype control reagent (anti-gD) as this antigen is absent 
in mice. Anti-gD was also conjugated with MMAE. Toxin 
conjugation via the engineered thiols was previously 
shown not to significantly alter their antigen binding or 
pharmacokinetics [21].
Radiolabeling of TENB2, STEAP1 and gD 
targeting mAbs
For ex vivo tumor uptake measurements, naked 
mAbs (without MMAE) were labeled. The naked mAb 
was chosen because the biology being interrogated 
(delivery, target binding, internalization) is independent 
of the drug conjugation, whereas using the ADC for 
radiolabeling introduces additional technical and logistical 
challenges to the experiment with essentially no benefit.
Indium-111 (111In) chelation was performed using 
2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic 
acid (DTPA; Macrocyclics) by methods previously 
described [22]. For immunoPET imaging, naked mAbs 
(without MMAE) were conjugated through side-chain 
lysines with a desferrioxamine B (Macrocyclics) chelating 
group using the benzyl isothiocyanate reagent and 
radiolabeled with 89Zr [7, 23, 24].
Quality control of the conjugated and radiolabeled 
mAbs was performed using size exclusion high-pressure 
liquid chromatography, measuring radiochemical purity 
and the presence of aggregates or fragments. Retention 
of antigen binding was tested using enzyme-linked 
immunosorbent assays (ELISA). For this a microplate 
was coated with TENB2 or STEAP1 extracellular domain. 
After coating, 0.5 mg/ml of bovine serum albumin (BSA) 
in PBS was added to the microplates and incubated at 4 °C 
for 1 h. After washing, the conjugated mAbs were added 
in concentrations ranging from 40 ng/ml to 0.066 ng/ml 
(in PBS + 0.05% BSA) and incubated for 1 h at ambient 
temperature. Thereafter 100 μl of 5 ng/ml anti-IgG Fab-
HRP was added to each microplate well and incubated 
for 1 h. After washing, 100 μl of SureBlue ReserveTM 
was added to each microplate well for 15 min at ambient 
temperature. Before measuring the optical density at 450 
nm for detection and 650 nm for absorbance, 100 μl of 0.6 
N sulfuric acid was added. A 4-parameter logistic curve 
fitting program was used to generate separate curves for 
each control (not conjugated) or conjugated mAbs. Based 
on this the potency was calculated.
Patient-derived xenograft models
Patient-derived human prostate cancer tissues 
(LuCaP35V, LuCaP70, LuCaP77, and LuCaP96.1) 
were kindly provided by Dr. R. Vessella (University of 
Washington). LuCaP35V is an androgen independent 
variant of LuCaP35 isolated from an inguinal lymph node 
metastasis [25]. LuCaP70, LuCaP77 and LuCaP96.1 were 
derived from liver, femur metastases or prostate tissue, 
respectively [26]. The patient-derived tumors have varying 
expression of TENB2 and STEAP1 that was determined 
ex vivo, as described below.
The LuCaP70, LuCaP77 and LuCaP96.1 patient 
derived xenografts were established through serial 
subcutaneous implantations of 20-30 mm3 tumor 
fragments in intact male CB17 SCID-beige mice. 
LuCaP35V was propagated in castrated mice (Charles 
River Laboratories). For all experiments mice were 
age matched and inoculated with the same tumors 
and designated into separate cohorts. Experiments 
were conducted more than a year apart in time and 
consequently on cohorts of tumors with somewhat 
different numbers of passages and growth properties 
because of the logistics of working with patient-derived 
xenograft models.
All animal studies were conducted in accordance to 
the guidelines of the Institutional Animal Care and Use 
Committee at Genentech, Inc.
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Dose-escalation pilot studies of 111In-labeled 
anti-STEAP1
The dose escalation study of 111In-anti-TENB2 was 
previously reported [23]. For the dose escalation study of 
111In-anti-STEAP1, LuCAP35V tumor bearing mice were 
dosed intravenously with approximately 0.18 MBq 111In-
labeled anti-STEAP1 (90 MBq/mg). Labeled tracer was 
mixed with cold mAb protein to achieve final dose levels 
of 0.08 mg/kg, 0.2 mg/kg, 1 mg/kg, 10 mg/kg, or 40 mg/
kg of STEAP1 per mouse (n = 5 per group). Tissues were 
harvested three days post-injection for gamma counting 
with the Wallac Wizard 1480 Automatic Gamma Counter 
(Perkin-Elmer).
Tumor tracer uptake and ADC growth inhibition 
studies
Cut-and-count tumor tracer uptake studies were 
performed in LuCaP35V, LuCaP70, LuCaP77, and 
LuCaP96.1 patient-derived xenografts (n = 4-5 per group) 
following the intravenous injection of a single dose (5 mg/
kg) of mAb targeting TENB2, STEAP1, or gD (isotype 
control) radiolabeled with 111In (0.18-0.74 MBq). Ex 
vivo analysis was performed three days post-injection 
of tracer to allow for tissue uptake, mAb internalization, 
and sufficient background clearance. Tumors were 
harvested, blot-dried, and weighed for gamma counting 
with background subtraction and decay correction against 
dosing solution standards.
Tumor growth inhibition was also studied in 
LuCaP35V, LuCaP70, LuCaP77, and LuCaP96.1 patient-
derived xenografts following a single dose of 5 mg/kg 
(same dose as for tracer above) of the ADCs targeting 
TENB2, STEAP1 or gD (isotype control). This dose was 
chosen because it was efficacious in sensitive models yet 
well-tolerated by the animals in previous studies (data 
not shown). ADCs were administered intravenously via 
the tail vein (n = 8-10 per group). Tumor volume growth 
was monitored for up to 70 days. Tumor length (l, the 
longest dimension) and width (w, perpendicular to the 
length) were measured by calipers; tumor volume V was 
approximated as V = lw2/2.
PET imaging
89Zr-PET imaging studies of tumor tracer uptake were 
performed after the intravenous injection of a single dose 
of 5 mg/kg of the mAbs targeting TENB2, STEAP1, or gD 
(isotype control) radiolabeled with 89Zr (3.7 MBq; 30 MBq/
mg), in LuCaP35V, LuCaP70, LuCaP77, and LuCaP96.1 
patient-derived xenografts (n = 3-5 per group). PET imaging 
was conducted five days later using Siemens Inveon PET/
CT scanners (Siemens). Animals were lightly anesthetized 
for restraint with approximately 3.5% sevoflurane, and body 
temperature was maintained at 37 °C by warm airflow. PET 
scans were 15-30 minute static scans.
Region of interest measurements defined by using 
software tools were made on multiple axial slices of the 
tissues using IRW software (Siemens). Decay-corrected 
signal intensity of tumor was measured as percentage of 
the injected dose per gram (%ID/g), assuming a tissue 
density of 1 ml per 1 gram soft tissue.
Ex vivo tumor analysis
Tumor samples used for ex vivo characterization 
of target expression levels were derived from tumor 
fragments with the same number of passages and in 
the same cohort of mice and as were used for efficacy 
studies.
Immunohistochemical determination of 
antigen expression was performed on 4 μm sections 
from formalin-fixed paraffin-embedded tissue. The 
primary mAbs used for immunohistochemistry were 
chosen because of their ability to detect antigen in 
fixed tissue and they were not the same mAbs used 
in experiments with live animals or unfixed tissues. 
Staining for TENB2 was performed on the Discovery 
XT autostainer (Ventana Medical Systems). Tissue 
sections were incubated in 2.5 μg/ml humanized anti-
TENB2 primary mAb, clone PR-1, and then in 7.5 μg/
ml goat anti-human, biotin conjugated mAb (Vector 
Laboratories). Human IgG (Jackson Immunoresearch) 
was used as a negative control mAb. Detection 
was performed utilizing Ventana DabMAP. For 
STEAP1, tissue sections were incubated in 10 μg/ml 
sheep primary mAb and then in biotinylated donkey 
anti-sheep IgG (Jackson Immunoresearch). Tissue 
sections were treated with Ventana DABMap™ for 
the detection of signals and visualization through 
3,3′-diaminobenzidine as a chromogenic peroxidase 
substrate. Immunohistochemistry scoring was 
performed by a board-certified pathologist and is based 
on the intensity of positive staining observed in at least 
50% of tumor cells: “negative” indicates no detectable 
signal, “1+” indicates a weak signal, “2+” indicates a 
moderate signal, and “3+” indicates a strong signal.
For fluorescence-activated cell sorting (FACS) 
experiments, tumor tissues were harvested, chopped 
and macerated in cell dissociation buffer (Gibco-BRL, 
#13151014), strained and washed with FACS buffer (1% 
FBS and 2mM EDTA in PBS). Cells were centrifuged 
at 4°C and resuspended in 20 ml ACK lysis buffer (163 
mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA pH 7.4) 
again centrifuged and resuspended into FACS buffer 
before being dispensed into a 96-well plate where they 
were incubated for one hour on ice with 3 mg/ml mAbs 
(unlabeled mAbs targeting TENB2 or STEAP1). After 
washing, 2 mg/ml of a secondary anti-human IgG-Fc 
domain PE mAb was added and incubated on ice for 
an additional hour. Cells were washed three times and 
resuspended in 100 ml of FACS buffer with 0.5 mg/ml PI 
and analyzed using a FACS Calibur Flow Cytometer (BD).
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